G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men.

BACKGROUND A single base pair mutation in the prothrombin gene has recently been identified that is associated with increased prothrombin levels. Whether this mutation increases the risks of arterial and venous thrombosis among healthy individuals is controversial. METHODS AND RESULTS In a prospective cohort of 14 916 men, we determined the prevalence of the G20210A prothrombin gene variant in 833 men who subsequently developed myocardial infarction, stroke, or venous thrombosis (cases) and in 1774 age- and smoking status-matched men who remained free of thrombosis during a 10-year follow-up (control subjects). Gene sequencing was used to confirm mutation status in a subgroup of participants. Overall, carrier rates for the G20210A mutation were similar among case and control subjects; the relative risk of developing any thrombotic event in association with the 20210A allele was 1.05 (95% CI, 0.7 to 1.6; P=0.8). We observed no evidence of association between mutation and myocardial infarction (RR=0.8, P=0.4) or stroke (RR=1.1, P=0.8). For venous thrombosis, a modest nonsignificant increase in risk was observed (RR=1.7, P=0.08) that was smaller in magnitude than that associated with factor V Leiden (RR=3.0, P<0. 001). Nine individuals carried both the prothrombin mutation and factor V Leiden (5 controls and 4 cases). One individual, a control subject, was homozygous for the prothrombin mutation. CONCLUSIONS In a large cohort of US men, the G20210A prothrombin gene variant was not associated with increased risk of myocardial infarction or stroke. For venous thrombosis, risk estimates associated with the G20210A mutation were smaller in magnitude than risk estimates associated with factor V Leiden.

[1]  B. Dahlbäck,et al.  Resistance to activated protein C as a basis for venous thrombosis. , 1994, The New England journal of medicine.

[2]  B. Dahlbäck,et al.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Cumming,et al.  The prothrombin gene G20210A variant: prevalence in a U.K. anticoagulant clinic population , 1997, British journal of haematology.

[4]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[5]  J. Miletich,et al.  Inherited predisposition to thrombosis , 1993, Cell.

[6]  F R Rosendaal,et al.  Risk of Myocardial Infarction Associated With Factor V Leiden or Prothrombin Interaction of Coagulation Defects and Cardiovascular Risk Factors : Increased , 1998 .

[7]  N. Dzimiri,et al.  World distribution of factor V Leiden , 1996, The Lancet.

[8]  M. Makris,et al.  Co-inheritance of the 20210A Allele of the Prothrombin Gene Increases the Risk of Thrombosis in Subjects with Familial Thrombophilia , 1997, Thrombosis and Haemostasis.

[9]  P. Ridker,et al.  Factor V Leiden Mutation and the Risks for Thromboembolic Disease: A Clinical Perspective , 1997, Annals of Internal Medicine.

[10]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[11]  P. Ridker,et al.  Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. , 1997, JAMA.

[12]  J. Bruce Bullock,et al.  Risk of What , 1986 .

[13]  B. Dahlbäck,et al.  Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis , 1994, The Lancet.

[14]  T. Baglin,et al.  Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′‐untranslated region of the prothrombin gene , 1997, British journal of haematology.

[15]  P. Ridker,et al.  Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. , 1995, The New England journal of medicine.

[16]  B. Dahlbäck,et al.  The 20210 A Allele of the Prothrombin Gene Is a Common Risk Factor among Swedish Outpatients with Verified Deep Venous Thrombosis , 1997, Thrombosis and Haemostasis.

[17]  Final report on the aspirin component of the ongoing Physicians' Health Study. , 1989, The New England journal of medicine.

[18]  M. Prins,et al.  The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). , 1997, The New England journal of medicine.

[19]  P. Ridker,et al.  Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. , 1995, Circulation.

[20]  F. Rosendaal,et al.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study , 1993, The Lancet.

[21]  F R Rosendaal,et al.  A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. , 1997, Blood.

[22]  F F Costa,et al.  Prevalence of the Prothrombin Gene Variant (nt20210A) in Venous Thrombosis and Arterial Disease , 1997, Thrombosis and Haemostasis.

[23]  T. Raghunathan,et al.  Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A) , 1998, Stroke.